BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)
Supplemental material
Ann Rheum Dis
Supplementary Table 6. Self-reported systemic rheumatic disease activity and flare following COVID- 19 infection.
Non- breakthrough COVID-19
Breakthrough COVID-19
All rheumatic disease patients (N=280)
p-value
infection (N=116)
infection (N=164)
Self-reported SARD flare after COVID-19, n (%) Timing of self-reported SARD flare after COVID-19, n (%)
115 (41)
46 (40)
69 (42)
0.71
0.19
<1 week
32 (11)
17 (15)
15 (9)
1-4 weeks
49 (18)
20 (17)
29 (18)
4-12 weeks >12 weeks
26 (9)
7 (6) 2 (2)
19 (12)
8 (3)
6 (4)
Participant global assessment of disease activity before COVID-19 onset, mean ± SD Participant global assessment of disease activity at time of survey, mean ± SD Disease activity by RAPID-3 at time of survey Median score [IQR]
7.6 (2.3)
7.6 (2.4)
7.6 (2.3)
0.98
6.7 (2.7)
6.8 (2.5)
6.6 (2.8)
0.41
3.0 (1.3, 4.7)
3.0 (1.3, 4.7)
3.3 (1.3, 4.7)
0.48
Categorical score, n (%)
0.86
Remission (0)
17 (6)
6 (5)
11 (7)
Near remission (0.3-1.0) Low severity (1.3-2.0) Moderate severity (2.3- 4.0) High severity (4.3-10.0)
37 (13) 34 (12)
17 (15) 13 (11)
20 (12) 21 (13)
84 (30)
31 (27)
53 (32)
82 (29) 53 (32) COVID-19, coronavirus disease 2019; RAPID3, Routine Assessment of Participant Index Data 3; SARD, systemic autoimmune rheumatic disease 29 (25)
2022;0:1–9. doi: 10.1136/ard-2022-223439 Ann Rheum Dis , et al. Patel NJ
Powered by FlippingBook